Patents Assigned to APTEVO RESEARCH AND DEVELOPMENT LLC
  • Patent number: 11352426
    Abstract: The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 7, 2022
    Assignee: APTEVO RESEARCH AND DEVELOPMENT LLC
    Inventors: Philip Tan, John W. Blankenship
  • Publication number: 20180118823
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 3, 2018
    Applicant: APTEVO RESEARCH AND DEVELOPMENT LLC
    Inventors: Peter Armstrong THOMPSON, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Laura Sue GROSMAIRE, Robert BADER, William BRADY
  • Patent number: 9493564
    Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 15, 2016
    Assignee: APTEVO RESEARCH AND DEVELOPMENT LLC
    Inventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan